Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN1777 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Monotherapy with AGEN1777 | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days \[3 weeks\]). |
| AGEN1777 in combination with a PD-1 inhibitor | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days. |
| Name | Type | Description |
|---|---|---|
| AGEN1777 | DRUG | An immunoglobulin gamma (IgG1) antibody |
| a PD-1 inhibitor | DRUG | Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumor for which no acceptable standard therapy available or progressed on or after standard therapies. 2. Measurable disease on baseline imaging based on Response Evaluation Criter...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AGEN1777 is an investigational small molecule being studied for the treatment of advanced cancer, including advanced solid tumors. It is being developed by Agenus Inc. and has been evaluated in a Phase 1 clinical trial in participants with advanced solid tumors. It is not approved for any indication.
AGEN1777 targets TIGIT, a protein receptor. By binding to TIGIT, the small molecule is designed to act on this immune checkpoint target in advanced cancer. TIGIT is a protein target being explored in oncology drug development.
AGEN1777 is being developed by Agenus Inc., which trades under the ticker AGEN. The company is the sponsor of the clinical program evaluating this small molecule in advanced cancer.
AGEN1777 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 program has included one completed trial in participants with advanced solid tumors.
AGEN1777 has been studied in one Phase 1 trial, NCT05025085, titled A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors. The trial enrolled 25 participants in the United States, was controlled and randomized, and is now completed.